Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...

Descripció completa

Dades bibliogràfiques

Autors principals:	Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-05-01
Col·lecció:	Frontiers in Oncology
Matèries:	breast cancer BRCA germline PARP inhibitors olaparib talazoparib
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1158981/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!